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Abstract 
Sound science and regulatory measures in risk assessment appear to be insufficient to 
address the public’s disquiet regarding genetically modified foods. In response, international 
organisations such as the World Health Organisation and the Food and Agriculture 
Organisation (FAO) of the United Nations have begun to embrace a more holistic approach 
that now considers the scientific, regulatory and local requirements as well as the social and 
ethical impact of modern food biotechnologies.  
 
One enduring difficulty in incorporating ethical and social issues in policy development has 
been its procedure. Of particular concern is the question of how to manage an exploration of 
often complex and controversial topics in such a way that the different voices and social and 
ethical norms of citizens and stakeholders are taken into account without unduly stifling or 
endangering good policy development and decision-making.  
 
This paper discusses the benefits and risks of one emerging framework that can be 
constructed around four mutually supportive, universal ethical principles set out in an ethical 
matrix. A systematic approach can lead to deliberations that are rational and inclusive, while 
being at the same time open and collaborative. Such a framework might compare well with 
existing scientific risk management practices.  
 
Taken together, an integration of both the scientific and the ethical-social could be of 
paramount importance for a modern food biotechnology that has global ambitions, but which 
can easily be fractured by local or social incompatibilities without public participation and 
support.  
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Introduction 
From its inception, the introduction of modern food and crop biotechnologies into local, 
national and global markets has been controversial. Initial research indicated that citizens did 
not reject genetically modified plants and crops because they lacked scientific understanding 
and sophistication as was assumed by the industry and governments. Instead, rather than 
being ignorant of the science (Cook et al. 2004), the various publics were discontent with the 
“dominant scientific and policy institutions and their behaviours” (Wynne 2001, p. 473), and 
believed that not enough attention was directed towards the ethical and socio-economic 
impacts of specific product developments. In response, many governments introduced 
measures such as scientific risk analyses, the establishment of regulatory bodies, the 
labelling of GM foods, and even a code of ethics (Department of Innovation and Information 
Economy 2001). Although these moves did not markedly change attitudes, they might have 
assisted in making people aware that they can influence outcomes by participating in 
decision-making. The shift to participatory governance in policy decision-making is not 
confined to developed regions such as Australia and Europe. It is also an emergent element 
in many Asian countries and in Africa (Birner and Alcaraz 2004). Indeed, Article 23 of the 
Cartagena Protocol on Biosafety, which came into force on 11 September 2003, requires that 
countries engage their citizens in decision-making both for policy development and for 
decisions “regarding life modified organisms”.  
 
Community engagement in ethical decision-makings 
Public participatory mechanisms allow divergent actors to articulate and explore particular 
issues and mediate differences. While the aim of such approach is apparent, namely to 
deliver more holistic and harmonious outcomes for modern food biotechnologies (and other 
emergent technologies), the path to such outcomes is less clear. A number of options for 
participatory community engagement exist. The more common ones are public consultations, 
which invite the community to either submit written comments or present their views at public 
meetings; small focus groups, at which participants take part in structured discussions and 
are interviewed on specific issues; public fora, where citizens are presented with detailed 
information about a given issue by experts and invited to provide comments and suggestions; 
or quantitative surveys where a cross-section of society is contacted and asked to fill in a 
detailed questionnaire, the answers of which are subsequently analysed and evaluated by 
experts.  
 
These options are institutionalised approaches with an ethical dimension. They are loosely 
structured information exchange and information gathering devices and are directed towards 
the scientific domain of product development. Generally, they do not create sufficient space 
for the various publics to deliberate on the possible ethical and social impact of the 
development or to effectively influence the direction of the enterprise. Ethical deliberations 
need a different kind of framework, namely one that is able to accommodate diverse value 
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systems and that can address highly complex issues. One emergent approach is the Ethical 
Matrix, first developed by Mepham (2000), who suggested it for the ethical analysis of novel 
foods.  
 
The ethical matrix 
The ethical matrix is guided by ethical principles as described by Beauchamp and Childress 
(1979, 1994, 1999, 2001) or their modifications. It presents as a structured framework for 
rational ethical deliberations and decision-making. In its mechanics, the matrix is a grid of 
cells that identifies all stakeholders and is headed by a set of agreed upon ethical principles. 
The ethical matrix allocates prima facie moral status1 to human and non-human actors. The 
consequences of a particular technology are investigated for each of the identified 
stakeholders and transcribed into their corresponding cells (Mepham 2000, Table 1). Once 
every cell has been filled in, stakeholders consider all consequences so as to arrive at an 
ethically acceptable position. From a theoretical point of view, the principles-based framework 
combines deontological and consequentialist aspects and is grounded in the ‘common 
morality’ as outlined by Beauchamp and Childress (1979, 1994, 1999, 2001). It makes 
abstract ethical principles particular to different groups of actors and concrete in terms of the 
issue at hand.  
 
Table 1. The original ethical matrix (Mepham 2000) 
Respect for:  Wellbeing Autonomy Justice 
Treated organism e.g. Animal welfare e.g. Behavioral 
freedom 
Telos 
Producers (e.g. 
farmers) 
Adequate income 
and working 
conditions 
Freedom to adopt or 
not to adopt 
Fair treatment in 
trade and law 
Consumers Availability of safe 
food; acceptability 
Respect for 
consumer choice 
(e.g. labelling) 
Universal affordability 
of food 
Biota Protection of the 
biota 
Maintenance of 
Biodiversity 
Sustainability of 
Biotic populations 
 
If required, the various impacts could be weighed against each other and ranked in order of 
importance to reach an ethical decision.  
 
Advantages of an ethical matrix 
One of the major benefits of an ethical matrix is that it is able to separate out complex, 
sometimes interconnected issues into their respective components. When analysing specific 
cases, the visual representation and the ease and clarity with which the matrix can be read 
assists stakeholders to remain aware of the divergence of interests per principle. In order to 
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illustrate Mepham’s (2000) original matrix by example, the principle ‘wellbeing’ — a 
combination of Beauchamp and Childress (1979, 1994, 1999, 2001) principles of beneficence 
(doing good) and non-maleficence (not doing harm) — is being analysed with respect to four 
different stakeholders: the genetically modified organism itself, the producers, the consumers 
and other biota.  
 
Taking the principle of ‘wellbeing’ (benefits and harms) as an example, two possible positive 
impacts affecting the modified organism itself are identifiable, namely firstly, the GM plant 
does not have to compete with weeds for water or soil nutrients and secondly, infestations 
with pests are reduced. However, there are also potential harms in that the destruction of 
weeds may reduce the habitat for various non-target insects and invertebrates. For 
producers, one possible impact could be financial. For early adopters of the application (first-
mover advantage) growing a particular GM crop and building up experience may be an 
investment in a lucrative future. Financial benefits could also accrue from having to spend 
less on a pesticide or herbicide spraying routine. There are non-financial benefits, too, in that 
less spraying could protect farmers, their families and communities from possible harmful 
exposure to a variety of chemicals. On the other hand, early adopters may find that the 
modified seeds cannot be saved for subsequent plantings, because they might have been 
made sterile. This could negatively affect genetic diversity. Furthermore, the special 
pesticide/herbicide recommended for use with the GM crop may cause its own health 
hazards. From the point of view of the consumer, the fact that a given gene technology 
regulator determines the GM food to be safe to eat might in itself be a benefit. However, 
negative outcomes could also be possible. For example, scientific risk assessments may only 
test for isolated molecules and not for any long-term in vivo impacts on human health, where 
molecules constantly interact with each other. Lastly, when analysing the possible impacts on 
biota, a given novel GM crop may lead to a reduced overall use of pesticides or herbicides, 
thereby minimising the potential harmful load to the environment. On the negative side, 
however, it may also accelerate the appearance of resistant strains.  
 
These hypothetical impact assessments per stakeholder need to be repeated for the other 
two ethical principles above. It would be almost impossible to recall all possible 
consequences for all stakeholders. Therefore, in complex situations such as GM 
modifications, the shorthand, highly structured overview makes decision-making rational and 
more manageable. A further, secondary, benefit is the educative potential of the matrix, in that 
it is able to make other stakeholders aware of issues outside their own horizons.  
 
Kaiser and Forsberg (2001) were the first to apply Mepham’s (2000) model to ethically assess 
Norwegian fisheries for the year 2020. Their project was not only very complex, it was also 
future-orientated and had to deal with substantial scientific uncertainty, increasing complexity 
many times. The ethical matrix is further mentioned by Kaiser (2003) in the FAO/WHO expert 
4 
consultation on GM animals in Rome and has become part of a major study in Europe 
presently underway to assess “the value of an ethical matrix in the decision-making process 
and the outcomes of their use” (Kaiser et al. 2004). In their initial analysis of using an ethical 
matrix in a participatory process, Kaiser and Forsberg (2001) found that the conceptual 
device is liberal in approach, transparent, able to respect problems and arguments, capable 
to contrast stakeholder interests, and useful for making abstract concepts concrete for 
participants. But they also reported some disadvantages.  
 
The disadvantages of an ethical matrix 
While the benefits of working with an ethical matrix are evident, both Mepham (2000) as well 
as Kaiser and Forsberg (2001) point out its substantial limitations. Since the duties described 
are prima facie duties, meaning that some duties and obligations must come before others, 
conflict of interest situations between different duties and obligations will frequently arise, 
requiring compromises (Mepham 2001, p. 169). If the matrix is used to facilitate a 
participatory event (Kaiser 2004), stakeholders themselves will discuss what the most 
relevant moral features are of a given issue in relation to a particular principle and fill the cells 
accordingly.  
 
We contend that while an ethical matrix is appealing in its visual simplicity and reductionism, 
using this ‘tool’ as starting point for discussions on ethical issues does not represent the 
complexity of life and the complexity of issues at hand. Indeed, it is our conviction that a 
matrix would prevent a holistic, in-depth, critical analysis of assumed values and facts, risks 
and benefits, alternatives and choices. The ethical matrix can lead to the exclusion of 
stakeholders and important issues, can lead to a distortion, even misrepresentation, of 
outcomes and manipulation of participants. It is argued here that the utility of the matrix lies in 
its usefulness as policy tool, rather than as an ethics “tool”. As ethics “tool” it is too restrictive 
for a number of reasons. In the remainder of the paper, we will explore two of these aspects.  
 
Problem 1: Capacity differentials and differences in values 
Two realities of public participation events are the inequity in capacity of stakeholders coupled 
with their diversity of values, both of which influence potential outcomes. Since stakeholders 
are affected differently by a given technology, a careful balancing and weighing up of one cell 
against another is essential. This presents a major problem. Not only in terms of differences 
in value and standardisation of weighing, but also in terms of differentials in capacity.  
 
For example, one of the most stated reasons for pursuing modern food biotechnologies is to 
increase food security. A secure food system is one in which foods can be grown in a 
continuous way with existing ecological resources and minimal damage to present and future 
environments.  
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Globally, we have areas of severe malnutrition but also areas of over-nutrition, both of which 
lead to alarming public health problems. In areas of malnutrition, provided certain conditions 
can be met and provided the growing areas are appropriate, modern biotechnological 
methods may, for example, improve yield, or the level of vitamins, or the fatty acid 
composition of foods, all aiding nutrition. It might be possible to genetically engineer further 
benefits. For example, one could grow plants with less input of fertilisers, herbicides and 
insecticides. One could also modify plants for optimised shelf life to counter post-harvest 
losses. For our example here, the genome of plants could be modified in such a way that they 
can cope with poor growing conditions, like marginal lands, where soils may be depleted of 
nutrients, in soils with high salt content or other poor environmental conditions. However, 
other farmers living in the same area might disapprove of the intensive farming of marginal 
lands, believing that ecologically stressed environments and biota may become even more 
fragile. When considering these points under the principle of ‘wellbeing’, the matrix would 
show two opposing views. Which of the two views should be retained: farming marginal lands 
or not farming marginal lands? Which one should be excluded? Would it be justifiable to 
exclude legitimate issues?  
 
This could become especially problematic in cases where there is a substantial difference in 
capacity amongst stakeholders and a lack of experience in participatory engagement. In the 
face of hunger and malnutrition, some African countries may welcome biotechnology-driven, 
large-scale agricultural plantings, because the change in practice may promise better and 
more reliable crops. On the other hand, the new practice may cause harm, because it may 
affect the traditional structures of society build on rural tradition and a more individualistic 
small-holder farming system. In many of these countries, public policy development is largely 
top-down for a number of reasons: a high percentage of illiteracy amongst rural populations; 
ignorance of political and civic processes; a lack of participatory mechanisms and 
experiences; or financial constraints (Ushewokunze-Obatolu 2003). Under these 
circumstances, inequality in capacity would demand a high degree of integrity from the more 
powerful participants during deliberations about future biotechnology developments.  
 
In conflicting or inequitable situations, differences in capacity can affect the outcome of 
deliberations. In the context of modern food biotechnologies, biotechnology providers, funding 
bodies, representative scientists and regulators could be regarded as the capacity-stronger 
participants. They not only possess scientific expert knowledge, they are also accustomed to 
public arenas and well versed in public communication. They present their views 
authoritatively and rationally. Their effective use of language can become a key determiner of 
power and positioning. Further bias can be created by a powerful stakeholder’s unwillingness 
or incapacity not to present their issues to non-experts in the language of the expert scientist. 
Such oratorical devise could indeed be used strategically to intimidate and manipulate the 
listener(s), introducing yet another layer of bias into the discussions. 
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 In their capacity as biotechnology recipients, farmers, retailers, and consumers are more 
likely to belong to the less powerful and practised group. This could create additional tension 
between already polarised parties. Capacity-neutral or poor groups might have an equal 
opportunity to represent their view, but whether their voice is heard might be a different 
matter. They might feel intimidated by the conduct, language and perceived impatience of 
more powerful stakeholders. In other cases, their particular belief system and cultural 
background might endanger equality and equity in participation. Although leaders may be 
anxious for less powerful groups to participate in deliberations, a basic commitment to fair 
procedures is also needed, which could impose some guidelines prior to the discussions to 
establish the norms of conduct and conditions of discourse (Taylor 1999). When dealing with 
minority groups, other mechanisms have been recommended (Foundation on Inter-Ethnic 
Relations 1999).  
 
These measures can be further supported by ethical guidelines steering conduct and 
expected standards. In 2001, Queensland became the first state in Australia to establish a 
code of ethics for biotechnology to guide researchers and industry operating in Queensland 
(Department of Innovation and Information Economy 2001). Other Australian states, such as 
Victoria, are currently considering their own code of ethics for biotechnology. Since modern 
food biotechnologies increasingly become global in distribution and application, Gesche et al. 
(2004) have proposed an ethical framework led by a special ‘Global Code of Ethical Practice 
for Modern Food Biotechnologies’, when operating across nations. Abiding by its suggested 
principles of beneficence, non-maleficence, justice and fairness, and choice and self-
determination during meetings would help avoid that differences in power or conflicts of 
interest2 overshadow the participatory event.  
 
Problem 2: Selectivity of content 
The ethical matrix can be used in a number of ways (Kaiser et al. 2004). It is the nature of an 
ethical matrix to draw attention to positive and negative aspects of a given product 
development relative to a principle or with regards to a stakeholder. This offers an opportunity 
for a comparative weighting of impacts, which could be regarded as critical for making an 
ethical judgement (Kaiser et al. 2004). If weighting is the aim, the framing of issues per 
stakeholder per cell is critical. In order to illustrate problem 2, Table 2 presents a more 
elaborate matrix with different ethical principles and with the biotechnology provider included.  
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Table 2. A recent ethical matrix for GM foods and crops (Gesche et al. 2004)  
General ethical 
matrix for GM 
foods and 
crops 
Beneficence Non-
maleficence 
Justice and 
Fairness 
Choice and 
Self-
determination 
Biotech Industry  Increase 
shareholder 
value and 
profits; capacity 
building 
Barriers to 
trade; restrictive 
environments 
for innovations 
and creativity 
Fair regulations 
and legislations; 
protection of 
intellectual 
property/licensing;  
fair distributions of 
risks and benefits 
Freedom to 
access and 
grow markets; 
progression of 
research and 
development  
Producers 
(farmers) 
Secure income 
and sustainable 
agri-practices 
Dependence on 
strategies of 
biotech 
corporations; 
loss of 
traditional 
landraces 
Fair treatment in 
trade and law; 
respecting local 
values and 
traditions 
Freedom to 
adopt or not to 
adopt 
Consumers Food and 
nutritional 
security 
Food safety; 
unintended 
effects on 
human and 
environmental 
health 
Access and 
affordability; 
public 
participation in 
decision-making 
Labelling  
Access to 
alternatives 
Biota (animal 
and plant life) 
Maintaining and 
protecting 
biodiversity 
Detrimental 
impact on 
health and 
environment; 
conservation 
Sustainability; 
protection of 
natural resources; 
respecting the 
intrinsic and 
inherent value of 
non-human life 
“Behavioural 
freedom”, 
“respect for 
natural capacity”
 
When operating with an ethical matrix, it is expected that each principle will have no more 
than one or two expected unique outcomes per stakeholder in order to keep the matrix 
manageable. Each outcome would have been shaped by the stakeholders’ values. Some of 
these values could have been more unified than others. While the biotechnology provider is 
more likely to promote one value and one culture, namely, the cultural values of one 
organisation, the values of producers and consumers will not be as uniform, they may even 
contradict each other as we saw earlier, when we introduced the example of two groups of 
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farmers considering marginal land use. If two impacts conflict within a cell, how is one to 
choose or rank each one? If one expands the matrix and separates out those conflicting 
parties, little changes, because one view will still have to be regarded as more important than 
another. This may result in a somewhat diluted position and weaker stakeholders might find 
themselves disadvantaged. Often no synthesis of positions might be possible. In these cases, 
the matrix would either have to make it clear that the content is a compromise position, or it 
would have to offer a range of different perspectives. If the latter is to be avoided, an interim 
exercise, such as a multi-criterion mapping exercise (Stirling and Mayer 2000), might be 
asked for.  
 
Other issues can exacerbate the dilemma, such as how much influence is exercised by the 
more powerful or financially stronger parties at ranking. While an ethical matrix may appear to 
be catering for different value systems, it actually may present a filtered reality that may 
exclude a number of equally valid choices. How an issue is framed and expressed in the 
matrix is critical for decision-making. Therefore, it seems that the time spent determining 
which issue(s) to include in the matrix is more important that the matrix itself. The matrix 
might be a synthesis of different views and knowledges, giving a filtered view of positions and 
requiring considerable integrity of all involved in the decision-making. These factors may 
make judgments to be far from what we think it is. 
 
Using an ethical matrix for policy development  
The ethical matrix lends itself as a policy development tool, especially in situations where 
many societal attitudes, values and interests need to be accommodated. For policy 
development, a number of public participation opportunities exist, such as when developing a 
national biotechnology policy document or when developing a regulatory framework for 
genetically modified organisms. In these instances, governments may invite public comments 
and may also solicit information about the level of agreement and disagreement with 
particular points or positions. According to Glowka/FAO (2003): 
“Opening decision-making processes up to the public may help to ensure that decision 
makers have the best information at their disposal in order to evaluate the benefits and 
risks that modern biotechnology could present. Public participation could also help to 
ensure better transparency and accountability in decision-making.” 
 
When subsequently processing the information in order to arrive at a just decision, an ethical 
matrix would be useful to facilitate the process of dialogue, mutual learning and just decision-
making by displaying the ‘plurality of legitimate perspectives’ (Funtowicz and Ravetz 2003, p. 
8) for recollection and perhaps ranking.  
 
Even at this late stage, however, bias can still creep into the process. It is worth noting that 
without collecting accurate and objective data, policy decision-makers may become prisoners 
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of their own worldview and use of language. According to Cormick (2003) many policy 
decisions in Australia are based on public attitudes towards certain applications of gene 
technology and may also emerge from second-hand information channels and anecdotal and 
undifferentiated evidence. This means that if powerful stakeholders (e.g. biotechnology 
providers) would not be accessing accurate and objective data and information, they might 
not be aware of the actual ‘heteroglossia of voices’ and of other dimensions of the wider 
discourse (Cook et al. 2004, p. 444).  
 
Conclusion 
Emerging technologies require us to rethink strategies in risk analysis. While scientific risk 
analysis has seen many beneficial changes at the interphase of biotechnology industry and 
the publics, it is now urgent to find a framework with which to adequately and systematically 
analyse some of the ethical and social issues that may arise. Such undertaking would need to 
respond to the demands of the public for greater participation in decision-making by moving 
beyond public consultation processes and other top-down, expert-driven communication 
pathways towards participatory frameworks that are more accessible, inclusive, accountable, 
open, multi-directional and interdisciplinary. The ethical matrix could be one of those 
frameworks. An explicit open communication system would bring a number of benefits. In the 
first instance, it would protect the reputational framework of the biotechnology provider and 
regulator and preserve their bottom line. Furthermore, enhanced community engagement 
during all phases of product development would project a mature attitude towards farmers, 
retailers and consumers (and, through them, the environment). Moreover, it could encourage 
a wider cross-section of society to offer fresh and innovative ideas and their background 
knowledges to policy makers and create avenues to assess and evaluate any suggestions for 
improvement, thus also benefiting the biotechnology industry.  
 
While we believe that the ethical matrix is more suitable for policy development than for 
ethical decision-making because of some serious shortfalls, it could be used for both 
purposes, albeit with different intents.  
 
A thorough evaluation of ethical decision-making frameworks is currently underway in Europe 
and will provide valuable answers.  
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1 The term prima facie, literally means “at first glance”. It was introduced by W D Ross (1877–
1940). Ross thought that consequences do not make an action necessarily right or wrong. 
Instead, he believed that it is more important to consider the consequences in making certain 
moral choices. Ross listed several prima facie duties, such as duties of justice, beneficence 
and nonmaleficence (noninjury), which Beauchamp and Childress (1979) were to take up 
years later in their ethical principles. If two principles conflict, Ross believed to always act in 
such a way that the stronger prima facie duty takes precedence over the weaker one. Ross W 
D 1930, The Right and the Good, Oxford University Press, New York.  
2 A conflict of interest arises when a person is influenced by factors that inhibit their ability to 
act impartially. It is foremost an ethical issue, because it can result in wrong decisions causing 
harm. It is also unjust, because it might favour one stakeholder over another. Furthermore, it 
prevents stakeholders to act impartially, thus limits their choices. Conflict of interest can lead 
to intentional, sometimes subtle, biased behaviour. For example, when stakeholders are 
influenced by the presence of other stakeholders, who provide the capital for research or 
commercialisation. In cases where a conflict of interest may arise or may exist, it should be 
disclosed to all other stakeholders so as to preserve the integrity of the participatory process.  
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